Global Tumor Immune Checkpoint Inhibitor Therapy Supply, Demand and Key Producers, 2023-2029
The global Tumor Immune Checkpoint Inhibitor Therapy market size is expected to reach $ 92090 million by 2029, rising at a market growth of 7.7% CAGR during the forecast period (2023-2029).
Immune checkpoint inhibitors are some monoclonal antibody drugs developed for the corresponding immune checkpoints. inhibition
This report studies the global Tumor Immune Checkpoint Inhibitor Therapy production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Tumor Immune Checkpoint Inhibitor Therapy, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Tumor Immune Checkpoint Inhibitor Therapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Tumor Immune Checkpoint Inhibitor Therapy total production and demand, 2018-2029, (K Units)
Global Tumor Immune Checkpoint Inhibitor Therapy total production value, 2018-2029, (USD Million)
Global Tumor Immune Checkpoint Inhibitor Therapy production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Tumor Immune Checkpoint Inhibitor Therapy consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Tumor Immune Checkpoint Inhibitor Therapy domestic production, consumption, key domestic manufacturers and share
Global Tumor Immune Checkpoint Inhibitor Therapy production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Tumor Immune Checkpoint Inhibitor Therapy production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Tumor Immune Checkpoint Inhibitor Therapy production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).
This reports profiles key players in the global Tumor Immune Checkpoint Inhibitor Therapy market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG, Pfizer, Sanofi, Merck, Ono Pharmaceutical and Regeneron, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Tumor Immune Checkpoint Inhibitor Therapy market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Tumor Immune Checkpoint Inhibitor Therapy Market, By Region:
1. How big is the global Tumor Immune Checkpoint Inhibitor Therapy market?
2. What is the demand of the global Tumor Immune Checkpoint Inhibitor Therapy market?
3. What is the year over year growth of the global Tumor Immune Checkpoint Inhibitor Therapy market?
4. What is the production and production value of the global Tumor Immune Checkpoint Inhibitor Therapy market?
5. Who are the key producers in the global Tumor Immune Checkpoint Inhibitor Therapy market?
6. What are the growth factors driving the market demand?
Immune checkpoint inhibitors are some monoclonal antibody drugs developed for the corresponding immune checkpoints. inhibition
This report studies the global Tumor Immune Checkpoint Inhibitor Therapy production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Tumor Immune Checkpoint Inhibitor Therapy, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Tumor Immune Checkpoint Inhibitor Therapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Tumor Immune Checkpoint Inhibitor Therapy total production and demand, 2018-2029, (K Units)
Global Tumor Immune Checkpoint Inhibitor Therapy total production value, 2018-2029, (USD Million)
Global Tumor Immune Checkpoint Inhibitor Therapy production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Tumor Immune Checkpoint Inhibitor Therapy consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Tumor Immune Checkpoint Inhibitor Therapy domestic production, consumption, key domestic manufacturers and share
Global Tumor Immune Checkpoint Inhibitor Therapy production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Tumor Immune Checkpoint Inhibitor Therapy production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Tumor Immune Checkpoint Inhibitor Therapy production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).
This reports profiles key players in the global Tumor Immune Checkpoint Inhibitor Therapy market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG, Pfizer, Sanofi, Merck, Ono Pharmaceutical and Regeneron, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Tumor Immune Checkpoint Inhibitor Therapy market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Tumor Immune Checkpoint Inhibitor Therapy Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- PD-1/PD-L1
- CTLA-4
- Hospital
- Clinic
- Other
- AstraZeneca
- Bristol-Myers Squibb
- Roche Holdings AG
- Novartis AG
- Pfizer
- Sanofi
- Merck
- Ono Pharmaceutical
- Regeneron
- Innovent
1. How big is the global Tumor Immune Checkpoint Inhibitor Therapy market?
2. What is the demand of the global Tumor Immune Checkpoint Inhibitor Therapy market?
3. What is the year over year growth of the global Tumor Immune Checkpoint Inhibitor Therapy market?
4. What is the production and production value of the global Tumor Immune Checkpoint Inhibitor Therapy market?
5. Who are the key producers in the global Tumor Immune Checkpoint Inhibitor Therapy market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Tumor Immune Checkpoint Inhibitor Therapy Introduction
1.2 World Tumor Immune Checkpoint Inhibitor Therapy Supply & Forecast
1.2.1 World Tumor Immune Checkpoint Inhibitor Therapy Production Value (2018 & 2022 & 2029)
1.2.2 World Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029)
1.2.3 World Tumor Immune Checkpoint Inhibitor Therapy Pricing Trends (2018-2029)
1.3 World Tumor Immune Checkpoint Inhibitor Therapy Production by Region (Based on Production Site)
1.3.1 World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Region (2018-2029)
1.3.2 World Tumor Immune Checkpoint Inhibitor Therapy Production by Region (2018-2029)
1.3.3 World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Region (2018-2029)
1.3.4 North America Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029)
1.3.5 Europe Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029)
1.3.6 China Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029)
1.3.7 Japan Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Tumor Immune Checkpoint Inhibitor Therapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Tumor Immune Checkpoint Inhibitor Therapy Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Tumor Immune Checkpoint Inhibitor Therapy Demand (2018-2029)
2.2 World Tumor Immune Checkpoint Inhibitor Therapy Consumption by Region
2.2.1 World Tumor Immune Checkpoint Inhibitor Therapy Consumption by Region (2018-2023)
2.2.2 World Tumor Immune Checkpoint Inhibitor Therapy Consumption Forecast by Region (2024-2029)
2.3 United States Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
2.4 China Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
2.5 Europe Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
2.6 Japan Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
2.7 South Korea Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
2.8 ASEAN Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
2.9 India Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
3 WORLD TUMOR IMMUNE CHECKPOINT INHIBITOR THERAPY MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Manufacturer (2018-2023)
3.2 World Tumor Immune Checkpoint Inhibitor Therapy Production by Manufacturer (2018-2023)
3.3 World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Manufacturer (2018-2023)
3.4 Tumor Immune Checkpoint Inhibitor Therapy Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Tumor Immune Checkpoint Inhibitor Therapy Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Tumor Immune Checkpoint Inhibitor Therapy in 2022
3.5.3 Global Concentration Ratios (CR8) for Tumor Immune Checkpoint Inhibitor Therapy in 2022
3.6 Tumor Immune Checkpoint Inhibitor Therapy Market: Overall Company Footprint Analysis
3.6.1 Tumor Immune Checkpoint Inhibitor Therapy Market: Region Footprint
3.6.2 Tumor Immune Checkpoint Inhibitor Therapy Market: Company Product Type Footprint
3.6.3 Tumor Immune Checkpoint Inhibitor Therapy Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Value Comparison
4.1.1 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Comparison
4.2.1 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Consumption Comparison
4.3.1 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value (2018-2023)
4.4.3 United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2023)
4.5 China Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers and Market Share
4.5.1 China Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value (2018-2023)
4.5.3 China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2023)
4.6 Rest of World Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Tumor Immune Checkpoint Inhibitor Therapy Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 PD-1/PD-L1
5.2.2 CTLA-4
5.3 Market Segment by Type
5.3.1 World Tumor Immune Checkpoint Inhibitor Therapy Production by Type (2018-2029)
5.3.2 World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Type (2018-2029)
5.3.3 World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Tumor Immune Checkpoint Inhibitor Therapy Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Tumor Immune Checkpoint Inhibitor Therapy Production by Application (2018-2029)
6.3.2 World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Application (2018-2029)
6.3.3 World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 AstraZeneca
7.1.1 AstraZeneca Details
7.1.2 AstraZeneca Major Business
7.1.3 AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.1.4 AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 AstraZeneca Recent Developments/Updates
7.1.6 AstraZeneca Competitive Strengths & Weaknesses
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Details
7.2.2 Bristol-Myers Squibb Major Business
7.2.3 Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.2.4 Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Bristol-Myers Squibb Recent Developments/Updates
7.2.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
7.3 Roche Holdings AG
7.3.1 Roche Holdings AG Details
7.3.2 Roche Holdings AG Major Business
7.3.3 Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.3.4 Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Roche Holdings AG Recent Developments/Updates
7.3.6 Roche Holdings AG Competitive Strengths & Weaknesses
7.4 Novartis AG
7.4.1 Novartis AG Details
7.4.2 Novartis AG Major Business
7.4.3 Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.4.4 Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Novartis AG Recent Developments/Updates
7.4.6 Novartis AG Competitive Strengths & Weaknesses
7.5 Pfizer
7.5.1 Pfizer Details
7.5.2 Pfizer Major Business
7.5.3 Pfizer Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.5.4 Pfizer Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Pfizer Recent Developments/Updates
7.5.6 Pfizer Competitive Strengths & Weaknesses
7.6 Sanofi
7.6.1 Sanofi Details
7.6.2 Sanofi Major Business
7.6.3 Sanofi Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.6.4 Sanofi Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Sanofi Recent Developments/Updates
7.6.6 Sanofi Competitive Strengths & Weaknesses
7.7 Merck
7.7.1 Merck Details
7.7.2 Merck Major Business
7.7.3 Merck Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.7.4 Merck Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Merck Recent Developments/Updates
7.7.6 Merck Competitive Strengths & Weaknesses
7.8 Ono Pharmaceutical
7.8.1 Ono Pharmaceutical Details
7.8.2 Ono Pharmaceutical Major Business
7.8.3 Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.8.4 Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Ono Pharmaceutical Recent Developments/Updates
7.8.6 Ono Pharmaceutical Competitive Strengths & Weaknesses
7.9 Regeneron
7.9.1 Regeneron Details
7.9.2 Regeneron Major Business
7.9.3 Regeneron Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.9.4 Regeneron Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Regeneron Recent Developments/Updates
7.9.6 Regeneron Competitive Strengths & Weaknesses
7.10 Innovent
7.10.1 Innovent Details
7.10.2 Innovent Major Business
7.10.3 Innovent Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.10.4 Innovent Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Innovent Recent Developments/Updates
7.10.6 Innovent Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Tumor Immune Checkpoint Inhibitor Therapy Industry Chain
8.2 Tumor Immune Checkpoint Inhibitor Therapy Upstream Analysis
8.2.1 Tumor Immune Checkpoint Inhibitor Therapy Core Raw Materials
8.2.2 Main Manufacturers of Tumor Immune Checkpoint Inhibitor Therapy Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Tumor Immune Checkpoint Inhibitor Therapy Production Mode
8.6 Tumor Immune Checkpoint Inhibitor Therapy Procurement Model
8.7 Tumor Immune Checkpoint Inhibitor Therapy Industry Sales Model and Sales Channels
8.7.1 Tumor Immune Checkpoint Inhibitor Therapy Sales Model
8.7.2 Tumor Immune Checkpoint Inhibitor Therapy Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Tumor Immune Checkpoint Inhibitor Therapy Introduction
1.2 World Tumor Immune Checkpoint Inhibitor Therapy Supply & Forecast
1.2.1 World Tumor Immune Checkpoint Inhibitor Therapy Production Value (2018 & 2022 & 2029)
1.2.2 World Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029)
1.2.3 World Tumor Immune Checkpoint Inhibitor Therapy Pricing Trends (2018-2029)
1.3 World Tumor Immune Checkpoint Inhibitor Therapy Production by Region (Based on Production Site)
1.3.1 World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Region (2018-2029)
1.3.2 World Tumor Immune Checkpoint Inhibitor Therapy Production by Region (2018-2029)
1.3.3 World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Region (2018-2029)
1.3.4 North America Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029)
1.3.5 Europe Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029)
1.3.6 China Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029)
1.3.7 Japan Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Tumor Immune Checkpoint Inhibitor Therapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Tumor Immune Checkpoint Inhibitor Therapy Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Tumor Immune Checkpoint Inhibitor Therapy Demand (2018-2029)
2.2 World Tumor Immune Checkpoint Inhibitor Therapy Consumption by Region
2.2.1 World Tumor Immune Checkpoint Inhibitor Therapy Consumption by Region (2018-2023)
2.2.2 World Tumor Immune Checkpoint Inhibitor Therapy Consumption Forecast by Region (2024-2029)
2.3 United States Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
2.4 China Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
2.5 Europe Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
2.6 Japan Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
2.7 South Korea Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
2.8 ASEAN Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
2.9 India Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029)
3 WORLD TUMOR IMMUNE CHECKPOINT INHIBITOR THERAPY MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Manufacturer (2018-2023)
3.2 World Tumor Immune Checkpoint Inhibitor Therapy Production by Manufacturer (2018-2023)
3.3 World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Manufacturer (2018-2023)
3.4 Tumor Immune Checkpoint Inhibitor Therapy Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Tumor Immune Checkpoint Inhibitor Therapy Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Tumor Immune Checkpoint Inhibitor Therapy in 2022
3.5.3 Global Concentration Ratios (CR8) for Tumor Immune Checkpoint Inhibitor Therapy in 2022
3.6 Tumor Immune Checkpoint Inhibitor Therapy Market: Overall Company Footprint Analysis
3.6.1 Tumor Immune Checkpoint Inhibitor Therapy Market: Region Footprint
3.6.2 Tumor Immune Checkpoint Inhibitor Therapy Market: Company Product Type Footprint
3.6.3 Tumor Immune Checkpoint Inhibitor Therapy Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Value Comparison
4.1.1 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Comparison
4.2.1 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Consumption Comparison
4.3.1 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value (2018-2023)
4.4.3 United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2023)
4.5 China Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers and Market Share
4.5.1 China Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value (2018-2023)
4.5.3 China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2023)
4.6 Rest of World Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Tumor Immune Checkpoint Inhibitor Therapy Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 PD-1/PD-L1
5.2.2 CTLA-4
5.3 Market Segment by Type
5.3.1 World Tumor Immune Checkpoint Inhibitor Therapy Production by Type (2018-2029)
5.3.2 World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Type (2018-2029)
5.3.3 World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Tumor Immune Checkpoint Inhibitor Therapy Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Tumor Immune Checkpoint Inhibitor Therapy Production by Application (2018-2029)
6.3.2 World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Application (2018-2029)
6.3.3 World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 AstraZeneca
7.1.1 AstraZeneca Details
7.1.2 AstraZeneca Major Business
7.1.3 AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.1.4 AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 AstraZeneca Recent Developments/Updates
7.1.6 AstraZeneca Competitive Strengths & Weaknesses
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Details
7.2.2 Bristol-Myers Squibb Major Business
7.2.3 Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.2.4 Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Bristol-Myers Squibb Recent Developments/Updates
7.2.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
7.3 Roche Holdings AG
7.3.1 Roche Holdings AG Details
7.3.2 Roche Holdings AG Major Business
7.3.3 Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.3.4 Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Roche Holdings AG Recent Developments/Updates
7.3.6 Roche Holdings AG Competitive Strengths & Weaknesses
7.4 Novartis AG
7.4.1 Novartis AG Details
7.4.2 Novartis AG Major Business
7.4.3 Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.4.4 Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Novartis AG Recent Developments/Updates
7.4.6 Novartis AG Competitive Strengths & Weaknesses
7.5 Pfizer
7.5.1 Pfizer Details
7.5.2 Pfizer Major Business
7.5.3 Pfizer Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.5.4 Pfizer Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Pfizer Recent Developments/Updates
7.5.6 Pfizer Competitive Strengths & Weaknesses
7.6 Sanofi
7.6.1 Sanofi Details
7.6.2 Sanofi Major Business
7.6.3 Sanofi Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.6.4 Sanofi Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Sanofi Recent Developments/Updates
7.6.6 Sanofi Competitive Strengths & Weaknesses
7.7 Merck
7.7.1 Merck Details
7.7.2 Merck Major Business
7.7.3 Merck Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.7.4 Merck Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Merck Recent Developments/Updates
7.7.6 Merck Competitive Strengths & Weaknesses
7.8 Ono Pharmaceutical
7.8.1 Ono Pharmaceutical Details
7.8.2 Ono Pharmaceutical Major Business
7.8.3 Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.8.4 Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Ono Pharmaceutical Recent Developments/Updates
7.8.6 Ono Pharmaceutical Competitive Strengths & Weaknesses
7.9 Regeneron
7.9.1 Regeneron Details
7.9.2 Regeneron Major Business
7.9.3 Regeneron Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.9.4 Regeneron Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Regeneron Recent Developments/Updates
7.9.6 Regeneron Competitive Strengths & Weaknesses
7.10 Innovent
7.10.1 Innovent Details
7.10.2 Innovent Major Business
7.10.3 Innovent Tumor Immune Checkpoint Inhibitor Therapy Product and Services
7.10.4 Innovent Tumor Immune Checkpoint Inhibitor Therapy Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Innovent Recent Developments/Updates
7.10.6 Innovent Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Tumor Immune Checkpoint Inhibitor Therapy Industry Chain
8.2 Tumor Immune Checkpoint Inhibitor Therapy Upstream Analysis
8.2.1 Tumor Immune Checkpoint Inhibitor Therapy Core Raw Materials
8.2.2 Main Manufacturers of Tumor Immune Checkpoint Inhibitor Therapy Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Tumor Immune Checkpoint Inhibitor Therapy Production Mode
8.6 Tumor Immune Checkpoint Inhibitor Therapy Procurement Model
8.7 Tumor Immune Checkpoint Inhibitor Therapy Industry Sales Model and Sales Channels
8.7.1 Tumor Immune Checkpoint Inhibitor Therapy Sales Model
8.7.2 Tumor Immune Checkpoint Inhibitor Therapy Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Region (2018-2023) & (USD Million)
Table 3. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Region (2024-2029) & (USD Million)
Table 4. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Region (2018-2023)
Table 5. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Region (2024-2029)
Table 6. World Tumor Immune Checkpoint Inhibitor Therapy Production by Region (2018-2023) & (K Units)
Table 7. World Tumor Immune Checkpoint Inhibitor Therapy Production by Region (2024-2029) & (K Units)
Table 8. World Tumor Immune Checkpoint Inhibitor Therapy Production Market Share by Region (2018-2023)
Table 9. World Tumor Immune Checkpoint Inhibitor Therapy Production Market Share by Region (2024-2029)
Table 10. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Tumor Immune Checkpoint Inhibitor Therapy Major Market Trends
Table 13. World Tumor Immune Checkpoint Inhibitor Therapy Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Tumor Immune Checkpoint Inhibitor Therapy Consumption by Region (2018-2023) & (K Units)
Table 15. World Tumor Immune Checkpoint Inhibitor Therapy Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Tumor Immune Checkpoint Inhibitor Therapy Producers in 2022
Table 18. World Tumor Immune Checkpoint Inhibitor Therapy Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Tumor Immune Checkpoint Inhibitor Therapy Producers in 2022
Table 20. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Tumor Immune Checkpoint Inhibitor Therapy Company Evaluation Quadrant
Table 22. World Tumor Immune Checkpoint Inhibitor Therapy Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Tumor Immune Checkpoint Inhibitor Therapy Production Site of Key Manufacturer
Table 24. Tumor Immune Checkpoint Inhibitor Therapy Market: Company Product Type Footprint
Table 25. Tumor Immune Checkpoint Inhibitor Therapy Market: Company Product Application Footprint
Table 26. Tumor Immune Checkpoint Inhibitor Therapy Competitive Factors
Table 27. Tumor Immune Checkpoint Inhibitor Therapy New Entrant and Capacity Expansion Plans
Table 28. Tumor Immune Checkpoint Inhibitor Therapy Mergers & Acquisitions Activity
Table 29. United States VS China Tumor Immune Checkpoint Inhibitor Therapy Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Tumor Immune Checkpoint Inhibitor Therapy Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Tumor Immune Checkpoint Inhibitor Therapy Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Market Share (2018-2023)
Table 37. China Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Market Share (2018-2023)
Table 42. Rest of World Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Market Share (2018-2023)
Table 47. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Tumor Immune Checkpoint Inhibitor Therapy Production by Type (2018-2023) & (K Units)
Table 49. World Tumor Immune Checkpoint Inhibitor Therapy Production by Type (2024-2029) & (K Units)
Table 50. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Type (2018-2023) & (USD Million)
Table 51. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Type (2024-2029) & (USD Million)
Table 52. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Tumor Immune Checkpoint Inhibitor Therapy Production by Application (2018-2023) & (K Units)
Table 56. World Tumor Immune Checkpoint Inhibitor Therapy Production by Application (2024-2029) & (K Units)
Table 57. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Application (2018-2023) & (USD Million)
Table 58. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Application (2024-2029) & (USD Million)
Table 59. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Application (2024-2029) & (US$/Unit)
Table 61. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 62. AstraZeneca Major Business
Table 63. AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 64. AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. AstraZeneca Recent Developments/Updates
Table 66. AstraZeneca Competitive Strengths & Weaknesses
Table 67. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 68. Bristol-Myers Squibb Major Business
Table 69. Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 70. Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Bristol-Myers Squibb Recent Developments/Updates
Table 72. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 73. Roche Holdings AG Basic Information, Manufacturing Base and Competitors
Table 74. Roche Holdings AG Major Business
Table 75. Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 76. Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Roche Holdings AG Recent Developments/Updates
Table 78. Roche Holdings AG Competitive Strengths & Weaknesses
Table 79. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 80. Novartis AG Major Business
Table 81. Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 82. Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Novartis AG Recent Developments/Updates
Table 84. Novartis AG Competitive Strengths & Weaknesses
Table 85. Pfizer Basic Information, Manufacturing Base and Competitors
Table 86. Pfizer Major Business
Table 87. Pfizer Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 88. Pfizer Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Pfizer Recent Developments/Updates
Table 90. Pfizer Competitive Strengths & Weaknesses
Table 91. Sanofi Basic Information, Manufacturing Base and Competitors
Table 92. Sanofi Major Business
Table 93. Sanofi Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 94. Sanofi Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Sanofi Recent Developments/Updates
Table 96. Sanofi Competitive Strengths & Weaknesses
Table 97. Merck Basic Information, Manufacturing Base and Competitors
Table 98. Merck Major Business
Table 99. Merck Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 100. Merck Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Merck Recent Developments/Updates
Table 102. Merck Competitive Strengths & Weaknesses
Table 103. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 104. Ono Pharmaceutical Major Business
Table 105. Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 106. Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Ono Pharmaceutical Recent Developments/Updates
Table 108. Ono Pharmaceutical Competitive Strengths & Weaknesses
Table 109. Regeneron Basic Information, Manufacturing Base and Competitors
Table 110. Regeneron Major Business
Table 111. Regeneron Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 112. Regeneron Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. Regeneron Recent Developments/Updates
Table 114. Innovent Basic Information, Manufacturing Base and Competitors
Table 115. Innovent Major Business
Table 116. Innovent Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 117. Innovent Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 118. Global Key Players of Tumor Immune Checkpoint Inhibitor Therapy Upstream (Raw Materials)
Table 119. Tumor Immune Checkpoint Inhibitor Therapy Typical Customers
Table 120. Tumor Immune Checkpoint Inhibitor Therapy Typical Distributors
List of Figure
Figure 1. Tumor Immune Checkpoint Inhibitor Therapy Picture
Figure 2. World Tumor Immune Checkpoint Inhibitor Therapy Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Tumor Immune Checkpoint Inhibitor Therapy Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029) & (K Units)
Figure 5. World Tumor Immune Checkpoint Inhibitor Therapy Average Price (2018-2029) & (US$/Unit)
Figure 6. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Region (2018-2029)
Figure 7. World Tumor Immune Checkpoint Inhibitor Therapy Production Market Share by Region (2018-2029)
Figure 8. North America Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029) & (K Units)
Figure 9. Europe Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029) & (K Units)
Figure 10. China Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029) & (K Units)
Figure 11. Japan Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029) & (K Units)
Figure 12. Tumor Immune Checkpoint Inhibitor Therapy Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 15. World Tumor Immune Checkpoint Inhibitor Therapy Consumption Market Share by Region (2018-2029)
Figure 16. United States Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 17. China Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 18. Europe Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 19. Japan Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 20. South Korea Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 22. India Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Tumor Immune Checkpoint Inhibitor Therapy by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Tumor Immune Checkpoint Inhibitor Therapy Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Tumor Immune Checkpoint Inhibitor Therapy Markets in 2022
Figure 26. United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Market Share 2022
Figure 30. China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Market Share 2022
Figure 32. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Type in 2022
Figure 34. PD-1/PD-L1
Figure 35. CTLA-4
Figure 36. World Tumor Immune Checkpoint Inhibitor Therapy Production Market Share by Type (2018-2029)
Figure 37. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Type (2018-2029)
Figure 38. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Type (2018-2029) & (US$/Unit)
Figure 39. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 40. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Application in 2022
Figure 41. Hospital
Figure 42. Clinic
Figure 43. Other
Figure 44. World Tumor Immune Checkpoint Inhibitor Therapy Production Market Share by Application (2018-2029)
Figure 45. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Application (2018-2029)
Figure 46. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Application (2018-2029) & (US$/Unit)
Figure 47. Tumor Immune Checkpoint Inhibitor Therapy Industry Chain
Figure 48. Tumor Immune Checkpoint Inhibitor Therapy Procurement Model
Figure 49. Tumor Immune Checkpoint Inhibitor Therapy Sales Model
Figure 50. Tumor Immune Checkpoint Inhibitor Therapy Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
Table 1. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Region (2018-2023) & (USD Million)
Table 3. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Region (2024-2029) & (USD Million)
Table 4. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Region (2018-2023)
Table 5. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Region (2024-2029)
Table 6. World Tumor Immune Checkpoint Inhibitor Therapy Production by Region (2018-2023) & (K Units)
Table 7. World Tumor Immune Checkpoint Inhibitor Therapy Production by Region (2024-2029) & (K Units)
Table 8. World Tumor Immune Checkpoint Inhibitor Therapy Production Market Share by Region (2018-2023)
Table 9. World Tumor Immune Checkpoint Inhibitor Therapy Production Market Share by Region (2024-2029)
Table 10. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Tumor Immune Checkpoint Inhibitor Therapy Major Market Trends
Table 13. World Tumor Immune Checkpoint Inhibitor Therapy Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Tumor Immune Checkpoint Inhibitor Therapy Consumption by Region (2018-2023) & (K Units)
Table 15. World Tumor Immune Checkpoint Inhibitor Therapy Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Tumor Immune Checkpoint Inhibitor Therapy Producers in 2022
Table 18. World Tumor Immune Checkpoint Inhibitor Therapy Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Tumor Immune Checkpoint Inhibitor Therapy Producers in 2022
Table 20. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Tumor Immune Checkpoint Inhibitor Therapy Company Evaluation Quadrant
Table 22. World Tumor Immune Checkpoint Inhibitor Therapy Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Tumor Immune Checkpoint Inhibitor Therapy Production Site of Key Manufacturer
Table 24. Tumor Immune Checkpoint Inhibitor Therapy Market: Company Product Type Footprint
Table 25. Tumor Immune Checkpoint Inhibitor Therapy Market: Company Product Application Footprint
Table 26. Tumor Immune Checkpoint Inhibitor Therapy Competitive Factors
Table 27. Tumor Immune Checkpoint Inhibitor Therapy New Entrant and Capacity Expansion Plans
Table 28. Tumor Immune Checkpoint Inhibitor Therapy Mergers & Acquisitions Activity
Table 29. United States VS China Tumor Immune Checkpoint Inhibitor Therapy Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Tumor Immune Checkpoint Inhibitor Therapy Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Tumor Immune Checkpoint Inhibitor Therapy Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Market Share (2018-2023)
Table 37. China Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Market Share (2018-2023)
Table 42. Rest of World Based Tumor Immune Checkpoint Inhibitor Therapy Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Market Share (2018-2023)
Table 47. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Tumor Immune Checkpoint Inhibitor Therapy Production by Type (2018-2023) & (K Units)
Table 49. World Tumor Immune Checkpoint Inhibitor Therapy Production by Type (2024-2029) & (K Units)
Table 50. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Type (2018-2023) & (USD Million)
Table 51. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Type (2024-2029) & (USD Million)
Table 52. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Tumor Immune Checkpoint Inhibitor Therapy Production by Application (2018-2023) & (K Units)
Table 56. World Tumor Immune Checkpoint Inhibitor Therapy Production by Application (2024-2029) & (K Units)
Table 57. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Application (2018-2023) & (USD Million)
Table 58. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Application (2024-2029) & (USD Million)
Table 59. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Application (2024-2029) & (US$/Unit)
Table 61. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 62. AstraZeneca Major Business
Table 63. AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 64. AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. AstraZeneca Recent Developments/Updates
Table 66. AstraZeneca Competitive Strengths & Weaknesses
Table 67. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 68. Bristol-Myers Squibb Major Business
Table 69. Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 70. Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Bristol-Myers Squibb Recent Developments/Updates
Table 72. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 73. Roche Holdings AG Basic Information, Manufacturing Base and Competitors
Table 74. Roche Holdings AG Major Business
Table 75. Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 76. Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Roche Holdings AG Recent Developments/Updates
Table 78. Roche Holdings AG Competitive Strengths & Weaknesses
Table 79. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 80. Novartis AG Major Business
Table 81. Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 82. Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Novartis AG Recent Developments/Updates
Table 84. Novartis AG Competitive Strengths & Weaknesses
Table 85. Pfizer Basic Information, Manufacturing Base and Competitors
Table 86. Pfizer Major Business
Table 87. Pfizer Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 88. Pfizer Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Pfizer Recent Developments/Updates
Table 90. Pfizer Competitive Strengths & Weaknesses
Table 91. Sanofi Basic Information, Manufacturing Base and Competitors
Table 92. Sanofi Major Business
Table 93. Sanofi Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 94. Sanofi Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Sanofi Recent Developments/Updates
Table 96. Sanofi Competitive Strengths & Weaknesses
Table 97. Merck Basic Information, Manufacturing Base and Competitors
Table 98. Merck Major Business
Table 99. Merck Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 100. Merck Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Merck Recent Developments/Updates
Table 102. Merck Competitive Strengths & Weaknesses
Table 103. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 104. Ono Pharmaceutical Major Business
Table 105. Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 106. Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Ono Pharmaceutical Recent Developments/Updates
Table 108. Ono Pharmaceutical Competitive Strengths & Weaknesses
Table 109. Regeneron Basic Information, Manufacturing Base and Competitors
Table 110. Regeneron Major Business
Table 111. Regeneron Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 112. Regeneron Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. Regeneron Recent Developments/Updates
Table 114. Innovent Basic Information, Manufacturing Base and Competitors
Table 115. Innovent Major Business
Table 116. Innovent Tumor Immune Checkpoint Inhibitor Therapy Product and Services
Table 117. Innovent Tumor Immune Checkpoint Inhibitor Therapy Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 118. Global Key Players of Tumor Immune Checkpoint Inhibitor Therapy Upstream (Raw Materials)
Table 119. Tumor Immune Checkpoint Inhibitor Therapy Typical Customers
Table 120. Tumor Immune Checkpoint Inhibitor Therapy Typical Distributors
List of Figure
Figure 1. Tumor Immune Checkpoint Inhibitor Therapy Picture
Figure 2. World Tumor Immune Checkpoint Inhibitor Therapy Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Tumor Immune Checkpoint Inhibitor Therapy Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029) & (K Units)
Figure 5. World Tumor Immune Checkpoint Inhibitor Therapy Average Price (2018-2029) & (US$/Unit)
Figure 6. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Region (2018-2029)
Figure 7. World Tumor Immune Checkpoint Inhibitor Therapy Production Market Share by Region (2018-2029)
Figure 8. North America Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029) & (K Units)
Figure 9. Europe Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029) & (K Units)
Figure 10. China Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029) & (K Units)
Figure 11. Japan Tumor Immune Checkpoint Inhibitor Therapy Production (2018-2029) & (K Units)
Figure 12. Tumor Immune Checkpoint Inhibitor Therapy Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 15. World Tumor Immune Checkpoint Inhibitor Therapy Consumption Market Share by Region (2018-2029)
Figure 16. United States Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 17. China Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 18. Europe Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 19. Japan Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 20. South Korea Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 22. India Tumor Immune Checkpoint Inhibitor Therapy Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Tumor Immune Checkpoint Inhibitor Therapy by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Tumor Immune Checkpoint Inhibitor Therapy Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Tumor Immune Checkpoint Inhibitor Therapy Markets in 2022
Figure 26. United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Tumor Immune Checkpoint Inhibitor Therapy Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Market Share 2022
Figure 30. China Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Production Market Share 2022
Figure 32. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Type in 2022
Figure 34. PD-1/PD-L1
Figure 35. CTLA-4
Figure 36. World Tumor Immune Checkpoint Inhibitor Therapy Production Market Share by Type (2018-2029)
Figure 37. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Type (2018-2029)
Figure 38. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Type (2018-2029) & (US$/Unit)
Figure 39. World Tumor Immune Checkpoint Inhibitor Therapy Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 40. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Application in 2022
Figure 41. Hospital
Figure 42. Clinic
Figure 43. Other
Figure 44. World Tumor Immune Checkpoint Inhibitor Therapy Production Market Share by Application (2018-2029)
Figure 45. World Tumor Immune Checkpoint Inhibitor Therapy Production Value Market Share by Application (2018-2029)
Figure 46. World Tumor Immune Checkpoint Inhibitor Therapy Average Price by Application (2018-2029) & (US$/Unit)
Figure 47. Tumor Immune Checkpoint Inhibitor Therapy Industry Chain
Figure 48. Tumor Immune Checkpoint Inhibitor Therapy Procurement Model
Figure 49. Tumor Immune Checkpoint Inhibitor Therapy Sales Model
Figure 50. Tumor Immune Checkpoint Inhibitor Therapy Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
